Data visualisation application speeds lead discovery

Published: 31-Aug-2010
Manufacturing Research & Development

Merck Millipore has new software for visualising GPCR and kinase activity

The Life Science division of Merck KGaA, Merck Millipore has introduced a software application for visualising GPCR (G-protein coupled receptors), as well as kinase activity.

The new Data Analysis and Report Tool (DART) creates an interactive map of target profiling assay results and enables drug researchers to make faster, more informed decisions.

‘Lead profiling often requires sifting through hundreds or even thousands of data points to pinpoint targets for further optimization studies,’ said Paul Wilhite, senior manager of eBusiness at Merck Millipore. ‘This new online tool provides a unique, information-rich interface so scientists can rapidly narrow their research and effectively collaborate with colleagues.’

The application projects each compound's activity profile onto a map depicting clusters of target protein families. This map provides scientists with immediate graphical insight into cross-target interactions to help drive structure-activity relationship (SAR) studies. The application is fully customisable. Data limits, sizing, colours, and target subclasses can be adjusted in seconds, thereby turning numerical data into a graphical display that can highlight biologically significant conclusions. Additionally, selected target information is dynamically populated and includes the gene symbol and aliases; links to bioinformatics content and recent publications; as well as links to appropriate Merck Millipore products.

Users of Merck Millipore's KinaseProfiler and GPCRProfiler screening services can upload their data directly into the DART tool or enter other datasets manually to take advantage of the software's analytical power and presentation-quality images.

See more

You may also like

Research & Development

Scientists develop new technique to fight antimicrobial resistance

Read more
The team of researchers from the University of Leicester have developed a new technique to sequence phage genomes from individual plaques and hopes to use it to build fully characterised libraries of bacteriophages, expanding the number of candidates available to tackle drug-resistant infections

Trending Articles

  1. FDA issues first cGMP warning letter citing AI misuse in pharmaceutical manufacturing A Michigan-based lab has become the subject of the FDA's first dedicated enforcement action on artificial intelligence misuse in drug manufacturing — a landmark event with far-reaching implications for cGMP compliance across the pharmaceutical supply chain
  2. Miltenyi Biotec and CHA Biotech collaborate on BaEV lentiviral vector platform The pair will work to enhance CAR NK cell therapy manufacturing efficiency, combining Miltenyi Bioindustry's baboon envelope lentiviral vector platform with CHA Biotech's NK cell research expertise to improve gene delivery, scalability and cost of goods
  3. Epitopea receives MHRA approval for first-in-human trial of RNA vaccine for ovarian cancer The company has received regulatory approval from the MHRA and Regional Ethics Committee to initiate its OVACT Phase I/Ib clinical trial of CryptiVax-1001, an off-the-shelf mRNA immunotherapy targeting high-grade serous ovarian cancer
  4. Simplifying continuous operations: lowering the barrier to faster development Continuous manufacturing has long promised faster development, improved process understanding and, in the absence of scale-up, smoother commercialization. For many pharmaceutical R&D teams, those benefits are well understood. What still holds them back, however, is not scepticism about the concept; it’s the perceived effort required to implement it
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    UK clinical trial reforms come into force in largest regulatory overhaul in 20 years The MHRA and Health Research Authority are implementing the most significant package of clinical trial regulatory reforms in more than two decades, introducing faster assessment routes for lower-risk trials and mandatory registration of trial results

Upcoming event

CHEMUK 2026

20–21 May 2026 | Conference and Exhibition | Birmingham, UK See all

You may also like

Research & Development

Scientists develop new technique to fight antimicrobial resistance

The team of researchers from the University of Leicester have developed a new technique to sequence phage genomes from individual plaques and hopes to use it to build fully characterised libraries of bacteriophages, expanding the number of candidates available to tackle drug-resistant infections
Research & Development

Lancet Oncology Commission launches to examine future of academic cancer clinical trials amid funding and regulatory pressures

A global coalition of clinical investigators and patient representatives has launched the Lancet Oncology Commission to address the value and challenges of independent academic cancer clinical trials, amid growing concerns over regulatory complexity, limited public funding and the need for new international collaboration models
Manufacturing

Almac highlights SDS-PAGE approach for residual protein determination in new white paper

New white paper explores robust analytical method for residual protein detection in biocatalytic API manufacturing
Manufacturing

Reliable, high-performance pump for HPLC and UHPLC

Biotech Fluidics announce the ASI 540 – an affordable, standalone solvent delivery pump - design optimised for liquid chromatography applications
Manufacturing

BD and Suttons Creek collaborate to streamline combination product development for pharma and biotech

The new strategic collaboration will help pharmaceutical and biotech companies reduce development risk and regulatory complexity across drug-device combination products, including biologics and GLP-1 therapies
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

UK clinical trial reforms come into force in largest regulatory overhaul in 20 years

The MHRA and Health Research Authority are implementing the most significant package of clinical trial regulatory reforms in more than two decades, introducing faster assessment routes for lower-risk trials and mandatory registration of trial results
Manufacturing

Miltenyi Biotec and CHA Biotech collaborate on BaEV lentiviral vector platform

The pair will work to enhance CAR NK cell therapy manufacturing efficiency, combining Miltenyi Bioindustry's baboon envelope lentiviral vector platform with CHA Biotech's NK cell research expertise to improve gene delivery, scalability and cost of goods
Subscribe now